HCV Management Program Offers Triple Therapy Regimen
Share
Follow Us
New Hepatitis C Drugs to their HEPVisionsSM Therapy Management Program
(OPENPRESS) June 14, 2011 — The announcement comes on the heels of the FDA’s approval of Merck’s VictrelisTM and Vertex’s IncivekTM. Both drugs are approved for use in combination with peg interferon and ribavirin, creating a triple therapy regimen. Clinical trials have shown that using one of the two new drugs along with peg interferon and ribavirin drugs is more effective at producing a sustained virological response (SVR).
“Axium is pleased to add VictrelisTM and IncivekTM to the HEPVisionsSM program,” said Mark Montgomery, President and CEO of Axium Healthcare Pharmacy. “The new triple therapy regimen is complex and expensive. Careful patient education, monitoring, and adherence are keys to successful treatment.”
Continue reading this entire article:
http://www.theopenpress.com/index.php?a=press&id=107323
